508 related articles for article (PubMed ID: 16289015)
1. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
2. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
[TBL] [Abstract][Full Text] [Related]
3. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Ganguly A; Chakraborty P; Banerjee K; Chatterjee S; Basu S; Sarkar A; Chatterjee M; Choudhuri SK
Biometals; 2012 Feb; 25(1):149-63. PubMed ID: 21915630
[TBL] [Abstract][Full Text] [Related]
4. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.
Mookerjee A; Basu JM; Majumder S; Chatterjee S; Panda GS; Dutta P; Pal S; Mukherjee P; Efferth T; Roy S; Choudhuri SK
BMC Cancer; 2006 Nov; 6():267. PubMed ID: 17107616
[TBL] [Abstract][Full Text] [Related]
5. Menadione reduced doxorubicin resistance in Ehrlich ascites carcinoma cells in vitro.
Xu CJ; Zhang Y; Wang J; Zhang TM
Zhongguo Yao Li Xue Bao; 1998 May; 19(3):273-6. PubMed ID: 10375743
[TBL] [Abstract][Full Text] [Related]
6. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
7. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
9. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
10. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
11. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
12. Importance of glutathione and associated enzymes in drug response.
Shen H; Kauvar L; Tew KD
Oncol Res; 1997; 9(6-7):295-302. PubMed ID: 9406235
[TBL] [Abstract][Full Text] [Related]
13. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
Cole SP; Downes HF; Mirski SE; Clements DJ
Mol Pharmacol; 1990 Feb; 37(2):192-7. PubMed ID: 1968221
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff's base to overcome MDR in cancer.
Basu S; Ganguly A; Chakraborty P; Sen R; Banerjee K; Chatterjee M; Efferth T; Choudhuri SK
Biochimie; 2012 Jan; 94(1):166-83. PubMed ID: 22037022
[TBL] [Abstract][Full Text] [Related]
15. The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer.
Ganguly A; Chakraborty P; Banerjee K; Choudhuri SK
Eur J Pharm Sci; 2014 Jan; 51():96-109. PubMed ID: 24044945
[TBL] [Abstract][Full Text] [Related]
16. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
Ganguly A; Basu S; Banerjee K; Chakraborty P; Sarkar A; Chatterjee M; Chaudhuri SK
Mol Biosyst; 2011 May; 7(5):1701-12. PubMed ID: 21409205
[TBL] [Abstract][Full Text] [Related]
17. A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer.
Ghosh RD; Banerjee K; Das S; Ganguly A; Chakraborty P; Sarkar A; Chatterjee M; Choudhuri SK
Eur J Pharm Sci; 2013 Jul; 49(4):737-47. PubMed ID: 23665413
[TBL] [Abstract][Full Text] [Related]
18. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative.
Ganguly A; Banerjee K; Chakraborty P; Das S; Sarkar A; Hazra A; Banerjee M; Maity A; Chatterjee M; Mondal NB; Choudhuri SK
Biomed Pharmacother; 2011 Sep; 65(6):387-94. PubMed ID: 21715129
[TBL] [Abstract][Full Text] [Related]
19. An in vitro and in vivo study of a novel zinc complex, zinc N-(2-hydroxyacetophenone)glycinate to overcome multidrug resistance in cancer.
Ghosh RD; Das S; Ganguly A; Banerjee K; Chakraborty P; Sarkar A; Chatterjee M; Nanda A; Pradhan K; Choudhuri SK
Dalton Trans; 2011 Nov; 40(41):10873-84. PubMed ID: 21717020
[TBL] [Abstract][Full Text] [Related]
20. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
